Please assess the completion status of the following clinical trial:

Trial Title: Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* One of the following histologically confirmed diseases for which no curative surgical, radiotherapy, or chemotherapy programs are available and standard therapy offers, at best, a modest clinical benefit~  * Solid tumors~ * Gliomas~ * Non-Hodgkin's lymphoma~* Primary and metastatic CNS malignancies are eligible~* Evaluable or measurable disease~* CD34 count at least 2.0 cells/μL~* No bone marrow involvement~  * Histologically negative bone marrow biopsy~PATIENT CHARACTERISTICS:~Age:~* 18 to 70~Performance status:~* ECOG 0-2~Life expectancy:~* At least 12 weeks~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 8.5 g/dL~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~* AST and ALT less than 2.5 times normal~* Prothrombin time less than 1.2 times normal~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No acute cardiac disease by EKG~Pulmonary:~* No symptomatic pulmonary disease~Other:~* HIV negative~* No other severe comorbid conditions~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 2 months after study completion~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Chemotherapy~* No prior hematopoietic stem cell transplantation~Chemotherapy:~* No prior high-dose chemotherapy~* Prior adjuvant chemotherapy allowed~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy to 25% or more of bone marrow~Surgery:~* Not specified~Other:~* At least 4 weeks since prior myelosuppressive therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).